Non-nanoparticulate application forms of macrolides
US-2024180822-A1 · Jun 6, 2024 · US
US9333182B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9333182-B2 |
| Application number | US-201214241622-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 31, 2012 |
| Priority date | Aug 31, 2011 |
| Publication date | May 10, 2016 |
| Grant date | May 10, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided is an adhesive patch which has excellent rivastigmine storage stability and an increased skin permeability of rivastigmine to such an extent that the amount of percutaneous absorption required for treating Alzheimer's disease is obtained. This adhesive patch includes a backing and an adhesive layer containing rivastigmine and an alkyl (meth)acrylate-based copolymer that does not contain any acrylic monomer component having a carboxy group, the adhesive layer being laid on one side of and integrated with the backing.
Opening claim text (preview).
The invention claimed is: 1. An adhesive patch comprising: a backing; and an adhesive layer containing rivastigmine and an alkyl (meth)acrylate-based copolymer without containing any acrylic monomer component having a carboxy group, the adhesive layer being laid on one side of and integrated with the backing, wherein the alkyl (meth)acrylate-based copolymer includes a copolymer containing a 2-ethylhexyl acrylate component, a 2-ethylhexyl methacrylate component and an alkyl (meth)acrylate component having an alkyl group with six or more carbon atoms except 2-ethylhexyl (meth)acrylate, wherein a total amount of the 2-ethylhexyl acrylate component and the 2-ethylhexyl methacrylate component is from 40 to 95% by weight of the copolymer, and an amount of the alkyl (meth)acrylate component having an alkyl group with six or more carbon atoms except 2-ethylhexyl (meth)acrylate is from 5 to 60% by weight of the copolymer. 2. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate component has an alkyl group with 6 to 16 carbon atoms except 2-ethylhexyl (meth)acrylate. 3. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate-based copolymer includes a 1-vinyl-2-pyrrolidone component. 4. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate-based copolymer includes a copolymer (B) containing a 1-vinyl-2-pyrrolidone component and an alkyl acrylate component having an alkyl group with 1 to 12 carbon atoms. 5. The adhesive patch according to claim 1 , wherein rivastigmine is in a free base form. 6. The adhesive patch according to claim 1 , wherein the adhesive layer does not contain an antioxidant and a rivastigmine volatilization inhibitor.
of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Polyacrylates · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.